Monday, 24 Feb 2020

Biologic/Novel Rx

Date Typesort ascending Title Save
25 Jul 2019 Social FDA has approved Ruxience (rituximab-pvvr; Pfizer), a biosimilar to Rituxan for use in NHL, CLL, granulomatosis w/ polyangiitis (GPA) & microscopic polyangiitis;(NOT RA) THis is the 2nd RTX biosimilar. https://t.co/GuVG6S980j
13 Mar 2017 Social Review of severe alopecia areata 90pts Rx w/ Xeljanz: 20% nearly total regrowth, 58% >50% regrowth,77% some regrowth https://t.co/8BZwOqevct
17 Jun 2015 Social Metanalysis of 7 RCTs compares high vs low dose RTX in RA shows little clinical difference. Better Xray w/ high dose http://t.co/ySSo3gVKE8
07 Sep 2017 Social In 10yrs MTX/biologic use increased (40%/1.7% to 64%/27%) & rate of ortho surgery dropped (72 to 51/1000 pts in 2014 https://t.co/IE72n2YMPB
25 Feb 2016 Social How to manage patients who worry, wont do & negatively inclined re:health/meds - the negative narrator in your head https://t.co/KEeVcWVedr
16 Nov 2016 Social RT @rachelthuston: TCZ for clinical remission in GCA but doesn't fully suppress MR signals of vessel inflammation #ACR16 @RheumNow https://…
21 Nov 2019 Social FINCH3: FILGOTINIB studied in this cohort naive to MTX; interesting that safety data looks good! Maybe too early to tell. Abst# 927 https://t.co/AonswiGYG3 https://t.co/q3OU582WbT
21 Apr 2017 Social Small study of 13 alopecia pts (2 totalis, 7universalis); Xeljanz Rx 7/13 had >50% regrowth w/in 9 mos, 2 d/c https://t.co/w5OxVvdIvQ
28 Aug 2015 Social FDA issues guidance document- Nonproprietary Naming of Biological Products (includes biosimilars) http://t.co/lsLmHbQS0t
29 May 2018 Social RT @LCalabreseDO: Interesting study by a careful group of Irish investigators on new biologic approach to GCA- needs f/u!! Ustekinumab: N…
05 Nov 2017 Social RT @HealioRheum: Maternal #biologic use did not increase risk for opportunistic infections in #newborns https://t.co/1Iaj1awDK0 #ACR17 http…
06 May 2016 Social A FREE Patient Guide to Biologic Use - available now at the RheumNow Website. 13 pages jammed with Patient Education https://t.co/f4BJvLu84N
17 Jan 2020 Social Analysis of worldwide data on Abatacept shows that compared with other bDMARDs, ABA was not associated with an increased overall cancer risk [ROR 0.98 (95% CI 0.91, 1.05)], but may be increased for risk of melanoma [1.58 (95% CI 1.17, 2.08)] https://t.co/3EI52M5kIR
11 Jul 2016 Social 234 RA pts Tx w/ Rituxan x 28 mos. w/ retention rate of 57%. D/C assoc w/ higher age, SJC, no concomitant MTX use https://t.co/QRLR9mgP84
15 Jun 2018 Social RT @CreakyJoints: US physicians are more prone to continue biologics through pregnancy. Per a research poster presented at #EULAR2018 https…
31 Jan 2017 Social @jhoronjeff @pfizer @US_FDA You missed the point - this is the kind of study that must be done to get an interchangeability indication
02 May 2015 Social Are you Biosimilar Bonkers? Heres as collection of Reports, forecasts etc. http://buff.ly/1AtJ593 
20 Jul 2017 Social 7 pts w/ Active Refractory Takayasu arteritis Tx w/ RTX w/ mixed results - 3 achieved remission but 4 failed to resp https://t.co/rXSNc6qpTn
30 Aug 2016 Social Dr Carol Langford Gr Rounds - ANCA levels do NOT correlate well with disease activity and should not be used to guide therapy
08 Oct 2018 Social "Therapeutic Update: Biosimilars in Rheumatology" video series features nine experts talking about biosimilars, sponsored by Sandoz, Inc. Visit RheumNow to watch: https://t.co/1vmnEJqOSi #biosimilars https://t.co/WM1EINjFGy